The David H. Koch Institute for Integrative Cancer Research at MITThe David H. Koch Institute for Integrative Cancer Research at MIT

Massachusetts Institute of Technology

National Cancer Institute Cancer Center

Science + Engineering... Conquering Cancer Together

Here Be Dragonfly

Dragonfly, co-founded by KI director Tyler Jacks, launched its first clinical trial, a study of multiple solid tumor types, with a drug candidate called DF1001; the drug is the first from its TriNKET™ platform of NK cell-based immunotherapies to move into humans. The company also entered a partnership with AbbVie to help commercialize other candidates in its pipeline.